This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions.
Glossary
- DMT=
- disease-modifying therapy;
- EAE=
- experimental autoimmune encephalomyelitis;
- EDSS=
- Expanded Disability Status Scale;
- GA=
- glatiramer acetate;
- IFNβ=
- interferon beta;
- ITP=
- idiopathic thrombocytopenic purpura;
- IVIg=
- IV immunoglobulin;
- MS=
- multiple sclerosis;
- PML=
- progressive multifocal leukoencephalopathy;
- PPMS=
- primary progressive multiple sclerosis;
- RCT=
- randomized controlled trial;
- RRMS=
- relapsing remitting multiple sclerosis;
- SC=
- subcutaneously;
- TNFα=
- tumor necrosis factor α.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Glossary
- RECENT HEAD-TO-HEAD TRIALS: ABOUT EXPECTATIONS, UNSUBSTANTIATED PREJUDICES, AND PROBLEMS FOR FUTURE TRIALS
- DOSE COMPARISON TRIALS: “MORE” OFTEN DOES NOT HELP MORE
- PROGRESSIVE MS, STEPCHILD OF MS THERAPEUTICS
- FAILURE OF SMART CONCEPTS: DISAPPOINTMENT TURNING INTO KNOWLEDGE
- NEW ADVERSE REACTIONS: THE PRICE TO BE PAID FOR PROGRESS?
- OUTLOOK
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
- CME Course
More Online
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard